amyloid-beta peptide

amyloid-β peptide

major neurotoxic component of extracellular deposits found in patients with Alzheimer disease.
References in periodicals archive ?
Moreover, PFKFB3 inhibitor protects neurons from the amyloid-beta peptide, the main component of the amyloid plaques found in the brains of Alzheimer's disease patients.
Indeed, the amyloid-beta peptide A[beta]42 has been shown to be an agonist for FPR-like-1 (FPRL1); FPRL1 is strongly expressed by inflammatory cells infiltrating neuritic plaques in postmortem Alzheimer cerebral tissue and so may be involved in the cerebral inflammatory processes associated with this form of dementia [10].
Brites, "Bilirubin and amyloid-beta peptide induce cytochrome c release through mitochondrial membrane permeabilization.," Molecular medicine, vol.
Lee, "Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide," Proceedings of the National Academy of Sciences of the United States of America, vol.
(2009) Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. See comment in PubMed Commons below Proc Natl Acad Sci U S A 106: 20324-20329.
Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.
Palmeri, "Hormetic effect of amyloid-beta peptide in synaptic plasticity and memory," Neurobiology of Aging, vol.
Palumaa, "Interactions of Zn(ii) and Cu(ii) ions with Alzheimer's amyloid-beta peptide. Metal ion binding, contribution to fibrillization and toxicity," Metallomics, vol.
ACU-193 selectively binds to and captures soluble oligomers of the amyloid-beta peptide. Acumen intends to initiate a Phase I/IIa trial to demonstrate clinical proof-of-concept of the antibody in Alzheimer's disease.
Amyloid-beta peptide, particularly the 42-amino-acid peptide (Abeta(1-42)), is a principal component of senile plaques and is thought to be central to the pathogenesis of the disease.
The progression of Alzheimer's disease, the most common form of adult onset dementia worldwide, is marked by a rise in the body's level of amyloid-beta peptide. At present, the most reliable and sensitive diagnostic techniques are invasive, typically requiring a sample of cerebrospinal fluid.
This drug is a modulator of gamma-secretase, which is a protease that cleaves amyloid precursor protein to produce the amyloid-beta peptide that consists of amyloid plaques, a defining feature of Alzheimer's disease.